ADRX · ADARx Pharmaceuticals, Inc. · Investor Relations

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that, in connection with its upsized initial public offering of its common stock, the

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the

SAN DIEGO, Calif. ­­– August 24, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for onvuzosiran, an

– Ying Huang, Ph.D. appointed to Board of Directors, bringing deep experience spanning executive public biotech leadership, Wall Street and big pharma R&D – – Robert Ackles joins as Chief People Officer, bringing nearly three decades of biopharma leadership experience and a proven record of

SAN DIEGO, Calif. ­­– June 8, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that Phase 1/2 clinical data for onvuzosiran, an investigational small interfering RNA (siRNA) therapeutic candidate

– Brings more than 20 years of experience in investment banking advising biotech and other innovative growth companies on financial and corporate development strategy – SAN DIEGO, Calif. – March 24, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage biotechnology company developing

– Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 – – Positive results support ongoing Phase 3 clinical trial – SAN DIEGO, Calif. ­­– February 27, 2026 – ADARx Pharmaceuticals, Inc.

SAN DIEGO, Calif. ­­– February 20, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present Phase 1/2 clinical data and Phase 3 design for its onvuzosiran (also known asADX-324)

– Seasoned clinical development leader brings more than 25 years of deep expertise in clinical development and operations across biotech and healthcare industry – SAN DIEGO, Calif. ­­– February 5, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage biotechnology company developing

– Dr. Tagliaferri is a proven executive recognized for advancing innovative therapies across immunology, oncology and other serious diseases – SAN DIEGO, Calif. ­­– December 2, 2025 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA

– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the efficacy and safety of ADX-038 in patients with complement-mediated diseases – SAN DIEGO, Calif.